



PATENT
Docket No. 2026-4205

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Topalian, et al. Group Art unit : 1645
Serial No. : 08/533,895 Examiner : Caputa, A.
Filed : September 26, 1995
For : MHC CLASS II RESTRICTED MELANOMA ANTIGENS
AND THEIR USE IN THERAPEUTIC METHODS

RESPONSE TO OFFICIAL ACTION PURSUANT TO 37 C.F.R. §1.115

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Official Action mailed January 25, 1999, applicants present the following amendments and remarks.

IN THE CLAIMS

Please cancel claim 93 without prejudice.

Please amend the claims as follows

64.(amended) An isolated [MHC] Major Histocompatibility Complex Class II immunogenic derivative of tyrosinase, wherein said derivative comprises at least a 9 amino acid segment of a sequence selected from the group consisting of QNILLSNAPLGPQFP (Ty 56-70) (SEQ ID NO: 1), NILLSNAPLGPQFP (Ty 57-70) (SEQ ID NO: 2) DYSYLQDSDPDSFQD (Ty 448-462) (SEQ ID NO: 6), YSYLQDSDPDSFQD (Ty 449-462) (SEQ ID NO: 13), and SYLQDSDPDSFQD (Ty 450-462) (SEQ ID NO: 14).